Vectura Group have entered into a collaboration for the co development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease.
The co development aims to leverage Vectura’s expertise in the pharmaceutical and clinical/regulatory development of inhaled therapeutics with UCB’s biologics and immunology assets.
The co development will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system.
The companies will jointly co manage the programme, with UCB focusing on bioprocess and preclinical development and Vectura taking responsibility for the pharmaceutical and clinical development of the dry powder product through to clinical proof-of-concept.
Financial terms of the co development partnership have not been disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on UCB company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with UCB
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity